Public company intelligence preview
CONTEXT THERAPEUTICS INC
14 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: $795408.19 average total compensation across covered insiders.
Governance movement
Public aggregate: 0 governance events in the last year.
Institutional ownership
Public aggregate: 42 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
Context Therapeutics Inc. is a Healthcare sector, Biotechnology company focused on clinical-stage development of T-cell engaging bispecific antibodies for solid tumors. Its lead programs are CTIM-76 (CLDN6 x CD3), CT-95 (MSLN x CD3), and CT-202 (Nectin-4 x CD3), with the company currently in early clinical and preclinical stages rather than commercialization. It has no approved products, no product sales, and relies on third-party manufacturers and external partners for development and supply chain needs. The business is highly dependent on clinical trial execution, regulatory milestones, and intellectual property protection.
Executive Compensation Practices
Executive compensation at a company like Context Therapeutics is typically driven less by revenue growth and more by clinical development milestones, financing execution, and pipeline advancement. Because the company is pre-revenue and posting operating losses, pay structures likely emphasize base salary plus equity incentives such as stock options or restricted stock, with awards tied to patient dosing, interim data readouts, IND/CTA progress, and trial initiation milestones. In biotechnology, boards often use equity-heavy compensation to conserve cash while aligning management with long-term value creation from successful drug development. The company’s rising R&D spend, hiring-related G&A growth, and need to manage a long cash runway suggest executive incentives may also reflect capital efficiency and cash preservation.
Insider Trading Considerations
Insider trading patterns at a Biotechnology company like Context Therapeutics are often influenced by binary clinical events, such as interim trial data, first-patient dosing, regulatory submissions, and partnership or licensing milestones. Because the stock can react sharply to data readouts and financing needs, insiders may be especially sensitive to blackout periods and to trading around upcoming Phase 1 updates for CTIM-76 and CT-95, as well as first-in-human progress for CT-202. The company’s dependence on external financing also means insider sales or purchases may be viewed through the lens of runway management and confidence in future raises. Researchers should watch for trades around milestone announcements, license payments, and regulatory filing updates, since these events are likely to be the main catalysts for abnormal insider activity.
Unlock the full CNTX insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.